Chapter 1 - Remdesivir

This is a listing of all citations in this chapter.

1

Sydney Lupkin, “Putting a Price on COVID-19 Treatment Remdesivir,” *Remdesivir Priced At More Than $3,100 For A Course Of Treatment, NPR (May 8, 2020).

2

Kathryn Ardizzone, “Role of the Federal Government in the Development of Remdesivir,” KEI Briefing Note 2020:1 (Mar. 20, 2020).

3

Bill & Melinda Gates Foundation, Form 990-PF, 2016.

4

United States Securities and Exchange Commission, Gilead Sciences, Inc.. Form 10-K.

5

Allison DeAngelis, “Gilead, Gates Foundation join Watertown biotech’s $55M financing round,” Boston Business Journal (Jan. 29, 2019).

6

Bill & Melinda Gates Foundation, University of California San Francisco, (Sept. 2016).

7

Christopher Rowland, “Taxpayers paid to develop remdesivir but will have no say when Gilead sets the price,” Washington Post (May 26, 2020).

8

Gilead Sciences, “GlobalData offers view on Gilead’s suspension of Covid-19 trials in China, News-Medical Life Sciences,” (Apr. 29, 2020).

9

ClinicalTrials.gov, “Investigational Therapeutics for the Treatment of People With Ebola Virus Disease,” (Oct. 28, 2018).

10

ClinicalTrials.gov, “Investigational Therapeutics for the Treatment of People With Ebola Virus Disease,” (Oct. 28, 2018).

11

Erika Check Hayden, “Experimental drugs poised for use in Ebola outbreak,” Nature (May 18, 2018).

12

National Institutes of Health, “Investigational Drugs Reduce Risk of Death from Ebola Virus Disease, NIH News Release,” (Nov. 27, 2019).

13

Sabue Mulangu, “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” New England Journal of Medicine (Dec. 12, 2019).

14

Sabue Mulangu, “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” New England Journal of Medicine (Dec.12, 2019), at Table 2.

15

NIH Press Release, “NIH clinical trial of remdesivir to treat COVID-19 begins,” NIH (Feb. 25, 2020).

16

NIH Press Release, “NIH clinical trial of remdesivir to treat COVID-19 begins,” NIH (Feb. 25, 2020).

17

NIH Press Release, “NIH clinical trial of remdesivir to treat COVID-19 begins,” NIH (Feb. 25, 2020).

18

Andres Hill, et al, “Minimum costs to manufacture new treatments for COVID-19,” ScienceDirect Journal of Virus Eradication 6 no. 2 (Apr. 2020):61-69.

19

Angus Liu, “Fair price for Gilead’s COVID-19 med remdesivir? $4,460, cost watchdog says,” FIERCE Pharma (May 4, 2020).

20

Matthew Herper, “Gilead announces long-awaited price for Covid-19 drug remdesivir,” STAT (Jun. 29, 2020).

21

Angus Liu, “Gilead banks on blockbuster remdesivir with sunnier 2020 outlook,” FIERCE Pharma (Jul. 21, 2020).

22

Angus Liu, “Gilead banks on blockbuster remdesivir with sunnier 2020 outlook,” FIERCE Pharma (Jul. 21, 2020).

23

“Gillings School researchers receive $6M+ grant to fight infectious diseases,” UNC Gillings School of Global Public Health (Aug. 31, 2017).

24

NIH Funding: Awards by Location & Organization, Ralph S. Baric: summary for Fiscal Year 2017.

25

Reality Check Team, “Coronavirus: Was US money used to fund risky research in China?,” BBC (Aug. 2, 2021).

26

Understanding The Risk Of Bat Coronavirus Emergence, Award No. R01AI110964, US Dept. HHS.

27

Jon Cohen, “Quarantined at home now, U.S. scientist describes his visit to China’s hot zone,” Science (Mar. 6, 2020).

28

Zhang Yan, David Stanway, “China lab seeks patent on use of Gilead’s coronavirus treatment,” Reuters (Feb. 4, 2020).

29

Zhang Yan, David Stanway, “China lab seeks patent on use of Gilead’s coronavirus treatment,” Reuters (Feb. 4, 2020).

30

BMGF Press Release, “Bill & Melinda Gates Foundation, Wellcome, and Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19,” BMGF (Mar. 10, 2020).